Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children

Thakkar, Dhwanee; Tiwari, Aseem Kumar; Pabbi, Swati; Kapoor, Rohit; Aggarwal, Geet; Rastogi, Neha; Yadav, Satya Prakash

doi:10.1002/cnr2.1408

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Previous studies demonstrated its cost-effectiveness, safety, and comparable efficacy to conventional rhG-CSF for the management of CIN in adults, 9 children, and adolescents. 10,11 Pegfilgrastim, a PEGylated form of rhG-CSF (analog of filgrastim), was approved for use in children to reverse CIN and reduce the incidence of neutropenia-associated infections. 12,13 Although PEG-rhG-CSF (Brand name, Jinyouli) was approved for marketing in China in March 2012, its use has been limited to Chinese adults.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, the plasma half‐life of PEG‐rhG‐CSF could be extended to up to 47 h, with preserved solubility, bioavailability, and stability 8 . Previous studies demonstrated its cost‐effectiveness, safety, and comparable efficacy to conventional rhG‐CSF for the management of CIN in adults, 9 children, and adolescents 10,11 …”

Section: Introductionmentioning

confidence: 99%

“… 8 Previous studies demonstrated its cost‐effectiveness, safety, and comparable efficacy to conventional rhG‐CSF for the management of CIN in adults, 9 children, and adolescents. 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

Huang,

Lu,

Wang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF) can be used in pediatric patients. This study assessed the safety and efficacy of PEG‐rhG‐CSF as a primary prophylactic drug against neutropenia after chemotherapy in pediatric patients with solid tumors or non‐Hodgkin lymphoma (NHL). Patients and Methods This phase II study (between October 2020 and March 2022) enrolled pediatric patients with solid tumors or NHL treated with high‐intensity chemotherapy and with grade ≥3 myelosuppression for at least 14 days during chemotherapy. Prophylactic PEG‐rhG‐CSF was given at 100 μg/kg body weight (maximum total dosage of 6 mg) once 24–48 h following chemotherapy for two cycles. The primary endpoint was the incidence of PEG‐rhG‐CSF‐related adverse events (AEs). The key secondary endpoints were the rates of grade 3/4 neutropenia and febrile neutropenia (FN). Results This study included 160 pediatric patients with a median age of 6.22 (0.29, 18.00) years. Fifty‐eight patients (36.25%) were diagnosed with sarcoma. AEs potentially related to PEG‐rhG‐CSF included bone pain (n = 32), fatigue (n = 21), pain at the injection site (n = 21), and myalgia (n = 20). The rates of grade 3/4 neutropenia and FN during treatment were 57.28% and 29.45%, respectively. Conclusion PEG‐rhG‐CSF is well tolerated and effective in pediatric patients with solid tumors or NHL. These findings should be substantiated with further trials. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04547829.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

Huang,

Lu,

Wang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background and Aim: We report here our experience of using pegylated granulocyte colony stimulating factor (peg-GCSF) for peripheral blood stem cell (PBSC) mobilization in children. Methods and results:A total of nine children suffering from high-risk/relapsed solid tumors were mobilized with chemotherapy and peg-GCSF (100 microgram/kg single dose). Mean age was 7.7 years (range 2-15 years).The mean time from peg-GCSF administration to PBSC harvest was 9.7 days. Adequate stem cells (median dose 26.9 million/kg) could be harvested in all children by a single apheresis procedure. No major adverse events observed. Conclusion:It is feasible and safe to mobilize PBSC with peg-GCSF in children with cancer.

show abstract

Synergistic Effect of Human Chorionic Gonadotropin and Granulocyte Colony Stimulating Factor in the Mobilization of HSPCs Improves Overall Survival After PBSCT in a Preclinical Murine Model. Are We Far Enough for Therapy?

Cismaru,

Tomuleasa,

Jurj

et al. 2023

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children

Cited by 3 publications

References 19 publications

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis

Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children

Synergistic Effect of Human Chorionic Gonadotropin and Granulocyte Colony Stimulating Factor in the Mobilization of HSPCs Improves Overall Survival After PBSCT in a Preclinical Murine Model. Are We Far Enough for Therapy?

Contact Info

Product

Resources

About